Navigation Links
DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the fourth closing in a private placement consisting of approximately 2.0 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.6 million. The total amount raised in the private placement to date is $9.5 million.

Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.  The maximum offering in the Private Placement consisted of 9,375,000 units for gross proceeds of $7.5 million.  In addition, the placement agent has been granted an over-allotment option of up to 3,125,000 units to cover over-subscriptions for additional gross proceeds of up to $2.5 million.  The over-allotment option is being exercised in part in connection with this closing.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit;   
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
2. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
3. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
6. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
7. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
11. New Avenues to Market - Research Report on Isis Pharmaceuticals, Inc., Avon Products, Inc., Elizabeth Arden, Inc., Boyd Gaming Corporation and Ameristar Casinos, Inc.
Post Your Comments:
(Date:11/30/2015)... --> --> According to ... (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative Dentistry, ... Global Forecast to 2020", published by MarketsandMarkets, is expected to ... 5.2% during the forecast period from 2015 to 2020. ... spread through 167 P ages and in-depth TOC on ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... , Nov. 30, 2015 Booth #4303 – ... VAR ) will exhibit a broader array of products in ... Radiological Society of North America in ... at the meeting will feature X-ray components "At the Heart ... a line of products from Varian,s Claymount brand, and computer-aided ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced that ... Healthcare IT consulting, development and support company. The purchase will expand the capability ... DataTrade to extend the services currently provided by Healthjump. , Through ...
(Date:11/30/2015)... Columbia, Maryland (PRWEB) , ... November 30, 2015 ... ... human interactions could be of critical importance to the medical schools of the ... SIMmersion exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized ...
(Date:11/30/2015)... ... November 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created ... web-styled transitions to wipes with blur & drop shadow options. Utilize the controls ... from one clip to the next with TransPack's easily customizable styles. , ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
(Date:11/30/2015)... 2015 (PRWEB) , ... November ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, ...
Breaking Medicine News(10 mins):